UBS AM
LKFT

UBS AM’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

UBS AM’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15,685
Closed -$2.39M – 2641
2019
Q3 		$2.39M Buy
15,685
+1,145
+8% +$188K ﹤0.01% 1527
2019
Q2 		$1.87M Buy
14,540
+2,327
+19% +$276K ﹤0.01% 1629
2019
Q1 		$1.44M Buy
12,213
+1,108
+10% +$112K ﹤0.01% 1675
2018
Q4 		$1.02M Buy
+11,105
New +$1.13M ﹤0.01% 1749

Other funds holding LKFT

Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bessemer Group
Bessemer Group Woodbridge, New Jersey $63.6B AUM 28.76% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Public Employees Retirement Association of Colorado
Public Employees Retirement Association of Colorado Denver, Colorado $25.5B AUM 28.85% 1-Year Est. Return

UBS AM's LKFT Position: Q4 2019 in Review

UBS AM sold out of Lakefront Biotherapeutics American Depositary Shares (LKFT) in Q4 2019, closing a stake of 15,685 shares — an estimated $2.39M sold.

UBS AM first reported a position in LKFT in Q4 2018 and held it in 4 quarters. The position peaked at $2.39M in Q3 2019. 137 funds tracked by Wall St. Rank hold LKFT as of Q4 2019.

  • UBS AM reported no remaining Lakefront Biotherapeutics American Depositary Shares position as of Q4 2019 after selling out during the quarter.
  • UBS AM sold 15,685 Lakefront Biotherapeutics American Depositary Shares shares in Q4 2019, an estimated $2.39M.
  • UBS AM first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q4 2018 and held it in 4 quarters.
  • UBS AM's Lakefront Biotherapeutics American Depositary Shares position peaked at $2.39M in Q3 2019.
  • 137 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q4 2019.

Based on UBS AM's 13F filing for Q4 2019, filed 14 Feb 2020.